US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
DE19616486C5
(en)
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Method for lowering the blood glucose level in mammals
|
EP1019494B1
(en)
*
|
1997-09-29 |
2007-03-21 |
Point Therapeutics, Inc. |
Stimulation of hematopoietic cells in vitro
|
WO1999025719A1
(en)
*
|
1997-11-18 |
1999-05-27 |
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai |
Novel physiologically active substance sulphostin, process for producing the same, and use thereof
|
EP2433623A1
(en)
*
|
1998-02-02 |
2012-03-28 |
Trustees Of Tufts College |
Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
|
AU2007202745B2
(en)
*
|
1998-02-02 |
2010-11-18 |
1149336 Ontario, Inc. |
Method of regulating glucose metabolism, and reagents related thereto
|
US6255772B1
(en)
|
1998-02-27 |
2001-07-03 |
Micron Technology, Inc. |
Large-area FED apparatus and method for making same
|
DE19823831A1
(en)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
New pharmaceutical use of isoleucyl thiazolidide and its salts
|
DE19828113A1
(en)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs of Dipeptidyl Peptidase IV Inhibitors
|
DE19828114A1
(en)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs of unstable inhibitors of dipeptidyl peptidase IV
|
DE19834591A1
(en)
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
US20050272652A1
(en)
*
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
PT1171465E
(en)
|
1999-03-29 |
2004-12-31 |
Uutech Ltd |
ANALYSIS OF A GASTRIC INHIBITOR AND THEIR USE FOR THE TREATMENT OF DIABETES
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
DE19926233C1
(en)
|
1999-06-10 |
2000-10-19 |
Probiodrug Ges Fuer Arzneim |
Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
|
DE19940130A1
(en)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
New effectors of Dipeptidyl Peptidase IV for topical use
|
JP2003535034A
(en)
*
|
1999-11-12 |
2003-11-25 |
ギルフォード ファーマシューティカルズ インコーポレイテッド |
Dipeptidyl peptidase IV inhibitors and methods for producing and using dipeptidyl peptidase IV inhibitors
|
GB9928330D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
NZ519231A
(en)
*
|
1999-12-23 |
2004-05-28 |
Novartis Ag |
Use of nateglinide as an insulin secretion enhancer for treating impaired glucose metabolism
|
US6380398B2
(en)
|
2000-01-04 |
2002-04-30 |
Novo Nordisk A/S |
Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
ES2436610T3
(en)
*
|
2000-01-21 |
2014-01-03 |
Novartis Ag |
Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
JP2003520849A
(en)
*
|
2000-01-24 |
2003-07-08 |
ノボ ノルディスク アクティーゼルスカブ |
N-substituted 2-cyanopyrroles and -pyrrolines which are inhibitors of the enzyme DPP-IV
|
AU2001233622A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Novo-Nordisk A/S |
Inhibition of beta cell degeneration
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
CZ20023234A3
(en)
*
|
2000-03-31 |
2003-01-15 |
Probiodrug Ag |
Medicament against diabetes mellitus
|
PE20020617A1
(en)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
COMPOSITION INCLUDING AN AT1 RECEPTOR ANTAGONIST AND AN INSULIN SECRETION POTENTIAL OR AN INSULIN SENSITIZER
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
CN1471392A
(en)
*
|
2000-10-27 |
2004-01-28 |
ǰ������ҩ��ɷ�����˾ |
Method for the treatment of neurological and neuropsychological disorders
|
EP1891948A1
(en)
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Treatment of neurological and neuropsychological disorders
|
EE05358B1
(en)
*
|
2000-12-14 |
2010-12-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Steroid hormone product and method for its preparation
|
CA2433090A1
(en)
*
|
2000-12-27 |
2002-07-04 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
DE10100053A1
(en)
*
|
2001-01-02 |
2002-08-22 |
Keyneurotek Ag I G |
Use of enzyme inhibitors of dipeptidyl peptidase IV and aminopeptidase N and pharmaceutical preparations therefrom for the prevention and / or therapy of ischemia-related acute and chronic neurodegenerative processes and diseases
|
ATE353900T1
(en)
*
|
2001-02-24 |
2007-03-15 |
Boehringer Ingelheim Pharma |
XANTHINE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
|
DE60226723D1
(en)
|
2001-03-27 |
2008-07-03 |
Merck & Co Inc |
DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
US20030060494A1
(en)
*
|
2001-05-18 |
2003-03-27 |
Nobuyuki Yasuda |
Pharmaceutical use of N-carbamoylazole derivatives
|
FR2826003B1
(en)
*
|
2001-06-18 |
2003-08-15 |
Servier Lab |
NOVEL CYCLIC DERIVATIVES OF ALPHA-AMINO-GAMMA-HYDROXY-AMIDES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
WO2003000181A2
(en)
|
2001-06-20 |
2003-01-03 |
Merck & Co., Inc. |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
JP2004535433A
(en)
|
2001-06-20 |
2004-11-25 |
メルク エンド カムパニー インコーポレーテッド |
Dipeptidyl peptidase inhibitors for the treatment of diabetes
|
DE10150203A1
(en)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
DE60222667T2
(en)
|
2001-06-27 |
2008-07-17 |
Smithkline Beecham Corp. |
FLUORPYRROLIDINES AS DIPEPTIDYLPEPTIDASE INHIBITORS
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
JP2005504766A
(en)
*
|
2001-08-16 |
2005-02-17 |
プロバイオドラッグ アーゲー |
Use of a proline endopeptidase inhibitor to regulate intracellular signal cascade dependent inositol (1,4,5) triphosphate concentration.
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
EP2316470A3
(en)
|
2001-11-26 |
2011-08-24 |
Trustees Of Tufts College |
Peptidomimetic inhibitors of post-proline cleaving enzymes
|
AU2002349513B2
(en)
*
|
2001-11-26 |
2007-10-18 |
Asubio Pharma Co., Ltd. |
Medicinal compositions for nasal absorption
|
EP2769715A3
(en)
*
|
2001-11-26 |
2014-09-17 |
Trustees Of Tufts College |
Methods for treating autoimmune disorders, and reagents related thereto
|
JP4359146B2
(en)
|
2002-02-13 |
2009-11-04 |
エフ.ホフマン−ラ ロシュ アーゲー |
Novel pyridine- and pyrimidine-derivatives
|
ATE309988T1
(en)
|
2002-02-13 |
2005-12-15 |
Hoffmann La Roche |
NEW PYRIDINE AND QUINOLINE DERIVATIVES
|
US7074798B2
(en)
|
2002-02-25 |
2006-07-11 |
Eisai Co., Ltd |
Xanthine derivative and DPPIV inhibitor
|
HUP0600057A2
(en)
|
2002-02-28 |
2006-05-29 |
Prosidion Ltd |
Glutaminyl based dpiv inhibitors, pharmaceutical compositions comprising thereof and their use
|
GB0205693D0
(en)
*
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
DE10211555A1
(en)
*
|
2002-03-15 |
2003-10-02 |
Imtm Inst Fuer Medizintechnolo |
Use of the inhibitors of enzymes with activities of the aminopeptidase N and / or the dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of dermatological diseases with sebocytic hyperproliferation and changed differentiation states
|
JP2005526811A
(en)
*
|
2002-03-25 |
2005-09-08 |
メルク エンド カムパニー インコーポレーテッド |
Β-amino heterocyclic dipeptidyl peptidase inhibitor for the treatment or prevention of diabetes
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
CN101273987A
(en)
*
|
2002-06-03 |
2008-10-01 |
诺瓦提斯公司 |
Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
CA2490818A1
(en)
*
|
2002-07-15 |
2004-01-22 |
Merck & Co., Inc. |
Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
|
US7407955B2
(en)
*
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
*
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
WO2004031374A2
(en)
*
|
2002-09-18 |
2004-04-15 |
Prosidion Ltd. |
Secondary binding site of dipeptidyl peptidase iv (dp iv)
|
US7262207B2
(en)
|
2002-09-19 |
2007-08-28 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
DE60315687T2
(en)
*
|
2002-10-07 |
2008-06-05 |
Merck & Co., Inc. |
ANTIDIABETIC HETEROCYCLIC BETA AMINO BINDINGS AS INHIBITORS OF DIPEPTIDYLPEPTIDASE
|
NZ538897A
(en)
*
|
2002-10-18 |
2007-02-23 |
Merck & Co Inc |
Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
DE60310991T2
(en)
|
2002-11-07 |
2007-10-18 |
Merck & Co, Inc. |
PHENYL ALANOL DERIVATIVES AS AN INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
|
US7482337B2
(en)
*
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(en)
*
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New xanthine derivatives, their production and their use as medicines
|
CA2508487A1
(en)
*
|
2002-12-04 |
2004-06-17 |
Merck & Co., Inc. |
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20060052382A1
(en)
*
|
2002-12-20 |
2006-03-09 |
Duffy Joseph L |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
CA2512546A1
(en)
|
2003-01-17 |
2004-08-05 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
AU2004210149A1
(en)
*
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
EP1595866B1
(en)
|
2003-01-31 |
2016-06-08 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome
|
US7550590B2
(en)
|
2003-03-25 |
2009-06-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
EP1961416B1
(en)
|
2003-05-05 |
2013-01-23 |
Probiodrug AG |
Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
|
WO2004098625A2
(en)
|
2003-05-05 |
2004-11-18 |
Probiodrug Ag |
Medical use of inhibitors of glutaminyl and glutamate cyclases
|
WO2004103276A2
(en)
|
2003-05-14 |
2004-12-02 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
JP2007511467A
(en)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
Dipeptidyl peptidase inhibitor
|
CA2526770A1
(en)
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
WO2004112701A2
(en)
|
2003-06-17 |
2004-12-29 |
Merck & Co., Inc. |
Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US7566707B2
(en)
*
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
CN101090901B
(en)
|
2003-06-20 |
2010-12-15 |
霍夫曼-拉罗奇有限公司 |
Hexahydropyridoisoqinolines as DPP-IV inhibitors
|
EP1638970B1
(en)
|
2003-06-20 |
2010-11-24 |
F. Hoffmann-La Roche AG |
Pyrid (2, 1-a) - isoquinoline derivatives as dpp-iv inhibitors
|
ES2328579T3
(en)
*
|
2003-07-25 |
2009-11-16 |
Conjuchem Biotechnologies Inc. |
LONG-TERM INSULIN DERIVATIVES AND ASSOCIATED PROCEDURES.
|
US7259160B2
(en)
|
2003-07-31 |
2007-08-21 |
Merck & Co., Inc. |
Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7470700B2
(en)
|
2003-08-13 |
2008-12-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1675578B9
(en)
*
|
2003-10-15 |
2014-06-25 |
Probiodrug AG |
Inhibitors of glutaminyl and glutamate cyclases for the treatment of the neurodegenerative diseases fbd and fdd
|
CA2543185A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Alza Corporation |
Compositions and dosage forms for ehnanced absorption of iron
|
EP2338490A3
(en)
|
2003-11-03 |
2012-06-06 |
Probiodrug AG |
Combinations useful for the treatment of neuronal disorders
|
US20100099721A1
(en)
*
|
2003-11-03 |
2010-04-22 |
Probiodrug Ag |
Novel compounds for the treatment of neurological disorders
|
US20050171112A1
(en)
*
|
2003-11-03 |
2005-08-04 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
CN1870990A
(en)
*
|
2003-11-04 |
2006-11-29 |
默克公司 |
Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US7767828B2
(en)
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
EP1743676A1
(en)
|
2003-11-12 |
2007-01-17 |
Phenomix Corporation |
Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2005049022A2
(en)
|
2003-11-17 |
2005-06-02 |
Novartis Ag |
Use of dipeptidyl peptidase iv inhibitors
|
DE10355304A1
(en)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel 8- (piperazin-1-yl) and 8 - ([1,4] diazepan-1-yl) xanthines, their preparation and their use as pharmaceuticals
|
BR122018073405B1
(en)
|
2004-01-20 |
2023-04-25 |
Novartis Ag |
PHARMACEUTICAL TABLET PRODUCED BY DIRECT COMPRESSION COMPRISING DIPEPTIDYLPEPTIDASE IV INHIBITOR
|
US7230002B2
(en)
|
2004-02-03 |
2007-06-12 |
Glenmark Pharmaceuticals Ltd. |
Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
|
KR101130433B1
(en)
|
2004-02-05 |
2012-03-27 |
교린 세이야꾸 가부시키 가이샤 |
Bicycloester derivative
|
BRPI0507485A
(en)
|
2004-02-05 |
2007-07-10 |
Probiodrug Ag |
new glutaminyl cyclase inhibitors
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(en)
*
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- [3-Amino-piperidin-1-yl] xanthines, their preparation and use as pharmaceuticals
|
EP1593671A1
(en)
*
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7393847B2
(en)
*
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
NZ549716A
(en)
|
2004-03-15 |
2010-04-30 |
Takeda Pharmaceutical |
Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
AU2005241056A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Merck & Co., Inc. |
1,2,4-oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
US7439370B2
(en)
*
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
JP2007538079A
(en)
*
|
2004-05-18 |
2007-12-27 |
メルク エンド カムパニー インコーポレーテッド |
Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
|
EP1598341A1
(en)
*
|
2004-05-21 |
2005-11-23 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV inhibitors
|
EP1753730A1
(en)
|
2004-06-04 |
2007-02-21 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1604989A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV inhibitors
|
EP1604980A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
DPP-IV inhibitors
|
DE102004030502A1
(en)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel imidazoles and triazoles, their preparation and use as medicines
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
AU2005267093B2
(en)
*
|
2004-07-23 |
2009-10-01 |
Nuada Llc |
Peptidase inhibitors
|
EP1623983A1
(en)
*
|
2004-08-05 |
2006-02-08 |
Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft |
Heterocyclic compounds useful as DPP-IV inhibitors
|
DE102004043944A1
(en)
*
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel 8- (3-amino-piperidin-1-yl) -7- (but-2-ynyl) -xanthines, their preparation and their use as pharmaceuticals
|
DE102004044221A1
(en)
*
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
EA013463B1
(en)
|
2004-10-12 |
2010-04-30 |
ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. |
Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, process for their preparation and method for the treatment using thereof
|
DE102004054054A1
(en)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
|
NZ554943A
(en)
*
|
2004-11-30 |
2010-12-24 |
Hoffmann La Roche |
Substituted benzoquinolizines as DPP-IV inhibitors for the treatment of diabetes
|
JP2008524276A
(en)
*
|
2004-12-20 |
2008-07-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
4-aminopiperidine derivatives
|
US7411093B2
(en)
|
2004-12-20 |
2008-08-12 |
Hoffman-La Roche Inc. |
Aminocycloalkanes as DPP-IV inhibitors
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
DOP2006000008A
(en)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
EP2392595A1
(en)
|
2005-02-11 |
2011-12-07 |
Amylin Pharmaceuticals Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
CN102372705A
(en)
|
2005-02-18 |
2012-03-14 |
田边三菱制药株式会社 |
Salt of proline derivative, solvate thereof, and production method thereof
|
US7553861B2
(en)
|
2005-04-22 |
2009-06-30 |
Alantos Pharmaceuticals Holding, Inc. |
Dipeptidyl peptidase-IV inhibitors
|
ATE486604T1
(en)
*
|
2005-04-26 |
2010-11-15 |
Mitsubishi Tanabe Pharma Corp |
PROPHYLACTIC/THERAPEUTIC AGENT FOR DEVIATIONS IN FAT METABOLISM
|
US7521557B2
(en)
*
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
EP1888101B1
(en)
|
2005-06-06 |
2012-03-21 |
Georgetown University |
Compositions and methods for lipo modeling
|
DE102005035891A1
(en)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
|
GT200600381A
(en)
|
2005-08-25 |
2007-03-28 |
|
ORGANIC COMPOUNDS
|
AU2006289259A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
|
WO2007028633A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Treatment of diabetes related obesity
|
PE20070522A1
(en)
|
2005-09-14 |
2007-07-11 |
Takeda Pharmaceutical |
2- [6- (3-AMINO-PIPERIDIN-1-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-ILMETHYL] -4-FLUORO-BENZONITRILE AS INHIBITOR OF DIPEPTIDIL PEPTIDASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
|
CA2622642C
(en)
|
2005-09-16 |
2013-12-31 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1971614A1
(en)
*
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
|
DE102005054994B4
(en)
*
|
2005-11-18 |
2015-02-12 |
Bader Gmbh & Co. Kg |
Cladding arrangement, in particular machine cladding, with a sliding door and guide arrangement therefor
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
AU2007224066B2
(en)
*
|
2006-03-08 |
2011-10-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
PE20071221A1
(en)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
|
ES2354390T3
(en)
|
2006-04-11 |
2011-03-14 |
Arena Pharmaceuticals, Inc. |
PROCEDURES FOR USE OF THE GPR119 RECEIVER TO IDENTIFY USEFUL COMPOUNDS TO INCREASE BONE MASS IN AN INDIVIDUAL.
|
US7728146B2
(en)
|
2006-04-12 |
2010-06-01 |
Probiodrug Ag |
Enzyme inhibitors
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
PE20110235A1
(en)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
EP2057160A1
(en)
*
|
2006-08-08 |
2009-05-13 |
Boehringer Ingelheim International GmbH |
Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
RS51965B
(en)
*
|
2006-09-13 |
2012-02-29 |
Takeda Pharmaceutical Company Limited |
Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
US8278345B2
(en)
|
2006-11-09 |
2012-10-02 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8217025B2
(en)
*
|
2006-11-17 |
2012-07-10 |
Harbor Therapeutics, Inc. |
Drug screening and treatment methods
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP5523107B2
(en)
|
2006-11-30 |
2014-06-18 |
プロビオドルグ エージー |
Novel inhibitors of glutaminyl cyclase
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
JPWO2008114857A1
(en)
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
Process for producing aminoacetylpyrrolidinecarbonitrile derivative
|
KR20120030570A
(en)
|
2007-04-03 |
2012-03-28 |
미쓰비시 타나베 파마 코퍼레이션 |
Combined use of dipeptidyl peptidase iv inhibitor compound and sweetener
|
EP2142514B1
(en)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
WO2008141021A1
(en)
|
2007-05-08 |
2008-11-20 |
Concert Pharmaceuticals, Inc. |
Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
|
EP2025674A1
(en)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
|
CL2008002427A1
(en)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
|
ES2733348T3
(en)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Purine derivatives for use in the treatment of diseases related to FAP
|
US20090076013A1
(en)
*
|
2007-09-17 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched sitagliptin
|
CL2008003653A1
(en)
*
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PE20140960A1
(en)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
FORMULATIONS INVOLVING A DPP4 INHIBITOR
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
PE20100156A1
(en)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
NAFLD TREATMENT
|
EP2650299A1
(en)
|
2008-07-03 |
2013-10-16 |
Ratiopharm GmbH |
Crystalline salts of sitagliptin
|
KR20200118243A
(en)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment for diabetes in patients inappropriate for metformin therapy
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
EP2322499A4
(en)
*
|
2008-08-07 |
2011-12-21 |
Kyorin Seiyaku Kk |
Process for production of bicycloý2.2.2¨octylamine derivative
|
US20110152342A1
(en)
*
|
2008-08-14 |
2011-06-23 |
Hiroshi Uchida |
Stabilized pharmaceutical composition
|
CN103816158A
(en)
*
|
2008-08-15 |
2014-05-28 |
勃林格殷格翰国际有限公司 |
Purin derivatives for use in the treatment of fab-related diseases
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
CN102316889B
(en)
|
2008-11-26 |
2014-11-26 |
萨蒂奥根制药公司 |
Compositions containing satiogens and methods of use
|
WO2010062861A2
(en)
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
MX2011006713A
(en)
|
2008-12-23 |
2011-07-13 |
Boehringer Ingelheim Int |
Salt forms of organic compound.
|
US8404727B2
(en)
|
2009-01-07 |
2013-03-26 |
Glenmark Pharmaceuticals S.A. |
Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
GEP20135962B
(en)
|
2009-02-13 |
2013-11-11 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising sglt2 inhibitor, dpp-iv inhibitor, and optionally further antidiabetic agent; and usage thereof
|
MX2011012198A
(en)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors.
|
WO2010130773A2
(en)
|
2009-05-15 |
2010-11-18 |
Novartis Ag |
Benzoxazolone derivatives as aldosterone symthase inhibitors
|
ES2602902T3
(en)
|
2009-05-28 |
2017-02-22 |
Novartis Ag |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
EP3048100A1
(en)
|
2009-05-28 |
2016-07-27 |
Novartis AG |
Substituted aminobutyric derivatives as neprilysin inhibitors
|
AR077642A1
(en)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
|
KR20120092096A
(en)
|
2009-09-02 |
2012-08-20 |
머크 샤프 앤드 돔 코포레이션 |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
CA2772488C
(en)
|
2009-09-11 |
2018-04-17 |
Probiodrug Ag |
Heterocyclic derivatives as inhibitors of glutaminyl cyclase
|
AU2010295646B2
(en)
|
2009-09-15 |
2016-02-11 |
Ellipses Pharma Limited |
Treatment of cancer
|
EP2501678B1
(en)
|
2009-11-17 |
2015-09-23 |
Novartis AG |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
|
US20110237540A1
(en)
|
2009-11-23 |
2011-09-29 |
Crawford Thomas C |
Cyclodextrin-based polymers for therapeutic delivery
|
KR20120107080A
(en)
|
2009-11-27 |
2012-09-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
EP2507234B1
(en)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazole derivatives as aldosterone synthase inhibitors
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US8269019B2
(en)
|
2010-03-10 |
2012-09-18 |
Probiodrug Ag |
Inhibitors
|
CA2795513A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
JP6034781B2
(en)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Combination therapy
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2011150286A2
(en)
|
2010-05-26 |
2011-12-01 |
Satiogen Pharmaceuticals,Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
AU2011268940B2
(en)
|
2010-06-24 |
2015-05-21 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
CN103221410B
(en)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
GPR119 receptor modulators and the treatment to relative obstacle
|
WO2012049566A1
(en)
|
2010-10-14 |
2012-04-19 |
Japan Tobacco Inc. |
Combination therapy for use in treating diabetes
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
UY33937A
(en)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
|
JP6050264B2
(en)
|
2011-03-16 |
2016-12-21 |
プロビオドルグ エージー |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145604A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2013006526A2
(en)
|
2011-07-05 |
2013-01-10 |
Merck Sharp & Dohme Corp. |
Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
|
NZ618698A
(en)
|
2011-07-15 |
2015-08-28 |
Boehringer Ingelheim Int |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20130109671A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9315508B2
(en)
|
2012-07-23 |
2016-04-19 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-IV inhibitors
|
TWI500613B
(en)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
Novel heterocyclic compounds
|
EP2911655A1
(en)
|
2012-10-24 |
2015-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
UY35144A
(en)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
APELINE SYNTHETIC LINEAR MIMETICS FOR THE CARDIAC INSUFFICIENCY TREATMENT
|
CN105073762B
(en)
|
2013-02-14 |
2017-03-08 |
诺华股份有限公司 |
Substituted biphenyl butyryl phosphonate derivative as NEP (neutral endopeptidase) inhibitor
|
AU2014293387B2
(en)
|
2013-07-25 |
2017-04-20 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
KR20160031551A
(en)
|
2013-07-25 |
2016-03-22 |
노파르티스 아게 |
Cyclic polypeptides for the treatment of heart failure
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
DE102014018663A1
(en)
|
2014-12-13 |
2015-03-05 |
Heinz Kiefer |
Detection of viable cells for the review of drug information in drug approval procedures
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
US9931372B2
(en)
|
2015-01-23 |
2018-04-03 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
SG10202103552XA
(en)
|
2015-03-09 |
2021-05-28 |
Intekrin Therapeutics Inc |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
IL285890B
(en)
|
2015-06-22 |
2022-07-01 |
Arena Pharm Inc |
Crystalline free-plate habit of l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid
|
MX2018007681A
(en)
|
2015-12-28 |
2018-11-14 |
Wockhardt Ltd |
An oral osmotic pharmaceutical composition of vildagliptin.
|
US11013738B2
(en)
*
|
2016-04-29 |
2021-05-25 |
Fundació Hospital Universitari Vall D'hebron—Institut De Recerca |
Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases
|
MX2018015089A
(en)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinations of linagliptin and metformin.
|
JOP20190086A1
(en)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
Naphthyridinone derivatives and their use in the treatment of arrhythmia
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
CN110996951A
(en)
|
2017-04-03 |
2020-04-10 |
科赫罗斯生物科学股份有限公司 |
PPAR gamma agonists for the treatment of progressive supranuclear palsy
|
ES2733477T3
(en)
|
2017-07-04 |
2019-11-29 |
Fis Fabbrica Italiana Sintetici Spa |
Effective procedure for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid
|
KR20200044016A
(en)
|
2017-08-24 |
2020-04-28 |
노보 노르디스크 에이/에스 |
GLP-1 composition and use
|
PL3461819T3
(en)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
UY38072A
(en)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
|
EP3524605B1
(en)
|
2018-02-13 |
2019-11-27 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
New efficient process for the preparation of sitagliptin
|
JP2022509184A
(en)
|
2018-11-27 |
2022-01-20 |
ノバルティス アーゲー |
Cyclic peptide as a proprotein convertase subbutyricin / kexin type 9 (PCSK9) inhibitor for the treatment of metabolic disorders
|
UY38485A
(en)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS, METHOD OF TREATMENT, USE AND PREPARATION
|
WO2020110008A1
(en)
|
2018-11-27 |
2020-06-04 |
Novartis Ag |
Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
|
EP3958857A1
(en)
|
2019-09-17 |
2022-03-02 |
Novartis AG |
Combination therapy with vildagliptin and metformin
|
BR112022013795A2
(en)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
LIQUID PHARMACEUTICAL COMPOSITION AND KIT
|
US20230285576A1
(en)
|
2020-08-05 |
2023-09-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
TW202333563A
(en)
|
2021-11-12 |
2023-09-01 |
瑞士商諾華公司 |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
AR127698A1
(en)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
|